Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Simvastatin/Ezetimibe

View presentation.

Public Citizen opposes approval of ezetimibe in combination with simvastatin for the proposed indication of reducing the risk of cardiovascular events in patients with coronary heart disease. Results of the IMPROVE-IT study failed to provide substantial evidence to support approval for this indication.